DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
DataMEDS AI (NASDAQ: MEDS) terminated the Second Amended and Restated letter of intent dated October 19, 2026 with Datavault AI (NASDAQ: DVLT) and four other parties covering in-license or acquisition of IP in exchange for DataMEDS common stock, citing market conditions. DVLT will no longer receive shares under the terminated LOI, and DataMEDS states it owes no fees or obligations as a result of the termination.
Key figures
- Loi date
- October 19, 2026
- Loi termination fee
- 0
- Related agreements preserved
- ["REBOOT exclusive GLP-1 management license (Oct 13, 2026)","Datavault AI PharmacyChain agreement (Nov 24, 2025)"]
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.